Journal
BRAIN PATHOLOGY
Volume 29, Issue 6, Pages 803-812Publisher
WILEY
DOI: 10.1111/bpa.12728
Keywords
alpha-synuclein; dementia with Lewy bodies; Lewy body disease; multiple system atrophy; NUB1; Parkinson's disease; phosphorylation; Synucleinopathy
Categories
Funding
- JSPS KAKENHI [17K07089, 17K07088, 18H02533]
- Hirosaki University Institutional Research Grant [2018-2810]
- Brain Research Institute, Niigata University [2018-2810]
- Karouji Memorial Fund for Medical Research
Ask authors/readers for more resources
Posttranslational modifications by phosphorylation, ubiquitination, neddylation and other pathways have emerged as major regulators of cellular functions. NEDD8 ultimate buster 1, NUB1, is an adaptor protein, which negatively regulates the levels of the ubiquitin-like protein NEDD8 as well as neddylated proteins through proteasomal degradation. We previously reported that NUB1 is highly involved in the pathogenesis of synucleinopathy including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). In general, since phosphorylation is strongly related to the alteration of protein propensity, we examined if the fundamental function of NUB1 can be modulated by its phosphorylation. We created a series of phosphomimic mutants of NUB1. Among them, we found that phosphorylation of NUB1 at S46 (P-NUB46) efficiently degrades aggregates using a cell-based assay. Immunohistochemical studies have shown that specific antibodies against P-NUB46 reacted with Lewy bodies in PD and DLB but not with glial cytoplasmic inclusions in MSA. Moreover, P-NUB46 levels were significantly higher in the brains of patients with DLB than in control brains, and P-NUB46 was extracted in an insoluble fraction of DLB. These findings suggest that the phosphorylation of NUB1 is modulated during the pathological process of Lewy body disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available